Notes
Comparative Effectiveness Public Advisory Council
Reference
Institute for Clinical and Economic Review. Institute for Clinical and Economic Review report finds inadequate evidence to compare PARP inhibitors across key ovarian cancer indications. Internet Document : 30 Aug 2017. Available from: URL: https://icer-review.org/announcements/parp-ovarian-evidence-report/
Rights and permissions
About this article
Cite this article
ICER report on PARP inhibitors for ovarian cancer. PharmacoEcon Outcomes News 786, 2 (2017). https://doi.org/10.1007/s40274-017-4292-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4292-1